Blog
About

3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Improving clinical outcomes using adoptively transferred immune cells from umbilical cord blood.

      Cytotherapy

      therapy, immunology, etiology, Virus Diseases, adverse effects, Transplantation Conditioning, metabolism, cytology, T-Lymphocytes, Regulatory, T-Lymphocyte Subsets, genetics, Recombinant Fusion Proteins, Receptors, Antigen, T-Cell, Killer Cells, Natural, Immunotherapy, Adoptive, Humans, Graft vs Host Disease, Fetal Blood, Cord Blood Stem Cell Transplantation

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Because of the necessary immunodepletion prior to cord blood transplantation as well as the immaturity of cord blood immune cells, recipients experience a high incidence of viral infection in addition to complications observed after hematopoietic stem cell transplantation, such as relapse and graft-versus-host disease. We describe current immunotherapeutic approaches to treating these complications, including the generation of antigen-specific T cells from cord blood, redirecting cord blood T cells using chimeric antigen receptors, and generating cord blood-derived natural killer cells and regulatory T cells.

          Related collections

          Author and article information

          Journal
          10.3109/14653249.2010.517518
          3178185
          20818913

          Comments

          Comment on this article